Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTT Cyteir Therapeutics	$3.01 -0.3%	$3.01	$1.65 ▼ $3.19	N/A	N/A	N/A	551,300 shs
LXRX Lexicon Pharmaceuticals	$0.45 +1.5%	$0.58	$0.28 ▼ $2.45	$111.05M	1.04	6.10 million shs	7.56 million shs
VERV Verve Therapeutics	$3.70 -4.0%	$6.70	$3.47 ▼ $9.31	$325.44M	1.77	1.42 million shs	862,223 shs
XERS Xeris Biopharma	$4.45 -8.9%	$4.28	$1.69 ▼ $6.07	$682.72M	1.37	1.80 million shs	1.97 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTT Cyteir Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
LXRX Lexicon Pharmaceuticals	-11.91%	+27.50%	+36.45%	-43.80%	-78.27%
VERV Verve Therapeutics	-1.53%	-27.08%	-37.09%	-38.30%	-55.80%
XERS Xeris Biopharma	-5.24%	-13.32%	+30.13%	+35.18%	+134.62%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTT Cyteir Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	3.1756 of 5 stars	4.2	3.0	0.0	0.0	3.1	1.7	0.6
VERV Verve Therapeutics	1.9827 of 5 stars	3.5	0.0	0.0	0.0	2.0	3.3	0.6
XERS Xeris Biopharma	4.3061 of 5 stars	4.4	1.0	0.0	4.2	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTT Cyteir Therapeutics	0.00	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	714.81% Upside
VERV Verve Therapeutics	3.00	Buy	$20.67	459.31% Upside
XERS Xeris Biopharma	2.80	Moderate Buy	$6.10	37.23% Upside

Current Analyst Ratings Breakdown

Latest CYTT, VERV, LXRX, and XERS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/25/2025	VERV Verve Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/7/2025	LXRX Lexicon Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $6.00
3/7/2025	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $6.00
3/7/2025	XERS Xeris Biopharma	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.50
3/7/2025	XERS Xeris Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $4.00
3/7/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.60 ➝ $8.00
3/5/2025	LXRX Lexicon Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/4/2025	LXRX Lexicon Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$2.00 ➝ $1.00
3/4/2025	VERV Verve Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTT Cyteir Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	$31.08M	3.57	N/A	N/A	$0.38 per share	1.18
VERV Verve Therapeutics	$32.33M	10.15	N/A	N/A	$7.31 per share	0.51
XERS Xeris Biopharma	$203.07M	3.37	N/A	N/A	($0.05) per share	-88.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTT Cyteir Therapeutics	-$46.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.64	N/A	N/A	N/A	-4,109.41%	-107.38%	-64.09%	5/1/2025 (Estimated)
VERV Verve Therapeutics	-$200.07M	-$2.35	N/A	N/A	N/A	-807.65%	-35.23%	-27.65%	5/14/2025 (Estimated)
XERS Xeris Biopharma	-$62.26M	-$0.38	N/A	N/A	N/A	-33.69%	N/A	-17.38%	5/8/2025 (Estimated)

Latest CYTT, VERV, LXRX, and XERS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	LXRX Lexicon Pharmaceuticals	-$0.10	N/A	N/A	N/A	$1.26 million	N/A
3/6/2025	Q4 2024	LXRX Lexicon Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	$6.48 million	$26.55 million
2/27/2025	Q4 2024	VERV Verve Therapeutics	-$0.72	-$0.58	+$0.14	-$0.58	$3.94 million	$13.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTT Cyteir Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTT Cyteir Therapeutics	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	0.56	7.45	7.43
VERV Verve Therapeutics	N/A	13.05	13.05
XERS Xeris Biopharma	N/A	1.79	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTT Cyteir Therapeutics	63.24%
LXRX Lexicon Pharmaceuticals	74.70%
VERV Verve Therapeutics	97.11%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
CYTT Cyteir Therapeutics	14.40%
LXRX Lexicon Pharmaceuticals	6.80%
VERV Verve Therapeutics	19.30%
XERS Xeris Biopharma	4.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTT Cyteir Therapeutics	46	36.00 million	30.81 million	N/A
LXRX Lexicon Pharmaceuticals	140	246.24 million	229.49 million	Optionable
VERV Verve Therapeutics	110	88.80 million	68.32 million	Optionable
XERS Xeris Biopharma	290	153.94 million	142.28 million	Optionable

CYTT, VERV, LXRX, and XERS Headlines

Recent News About These Companies

Xeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's Why

April 3 at 12:59 PM | marketbeat.com

AIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 31, 2025 | marketbeat.com

Xeris Announces Changes to Its Board of Directors

March 28, 2025 | finance.yahoo.com

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?

March 25, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 23, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 Shares

March 22, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's Why

March 22, 2025 | marketbeat.com

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

March 20, 2025 | zacks.com

12 Best Stocks to Invest in for a Stock Market Game

March 20, 2025 | insidermonkey.com

Xeris enters a whole new market for one of its main pharma offerings

March 20, 2025 | chicagobusiness.com

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

March 19, 2025 | insidermonkey.com

Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 18, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Sets New 12-Month High - Still a Buy?

March 18, 2025 | marketbeat.com

FDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aid

March 17, 2025 | markets.businessinsider.com

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

March 17, 2025 | finance.yahoo.com

Globeflex Capital L P Takes $424,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 17, 2025 | marketbeat.com

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator

March 16, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - Here's What Happened

March 15, 2025 | marketbeat.com

Xeris Biopharma Holdings Share Price (XERS.US)

March 12, 2025 | lse.co.uk

Xeris Biopharma (NASDAQ:XERS) Sets New 1-Year High - Should You Buy?

March 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTT, VERV, LXRX, and XERS Company Descriptions

Cyteir Therapeutics NASDAQ:CYTT

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.45 +0.01 (+1.53%)

As of 01:42 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Verve Therapeutics NASDAQ:VERV

$3.70 -0.16 (-4.03%)

As of 01:42 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Xeris Biopharma NASDAQ:XERS

$4.44 -0.44 (-8.91%)

As of 01:41 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time